# A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

> **NCT02322814** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 169 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo
- **DRUG:** Atezolizumab
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT02322814
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-12
- **Primary completion:** 2018-08-10
- **Final completion:** 2021-09-17
- **Target enrollment:** 169 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322814, "A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02322814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*